Clinical Trial Finder | Pancreatic Cancer Action Network

Back to Trial Search

Phase I Trial Study of Disulfiram and Gemcitabine in Solid Tumor and Pancreas Cancer Patients

Summary

The purpose of this phase I trial is to study the side effects and best dose of disulfiram when given together with gemcitabine hydrochloride in treating patients with an unresectable solid tumor or metastatic pancreatic cancer, and to compare whether disulfiram and gemcitabine hydrochloride may reduce tumor induced muscle loss.

General Information

NCT#: NCT02671890
Study ID: MC1512
Trial Phase: Phase I

Trial Sponsor: National Cancer Institute (NCI), Mayo Clinic
Therapies Used in This Trial: Gemcitabine, Disulfiram

Request a Healthcare Provider account to access Trial Eligibility and Site Information.

View Details

An authorized Healthcare Provider account is required to access Trial Eligibility and Site Information. Already have an account? Sign In

Request an Account

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account.
In order to view this information, you need to be signed in as a Health Care Provider.
In order to see the trial eligibility criteria, you need to be signed in as a Health Care Provider.
This information is restricted to validated Health Care Providers.

Eligibility

-------------------------------------------------------------------------------------------

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account by clicking on the Request button.
------------------------------------------------------------------------------------------------------
In order to view this information, you need to be signed in as a Health Care Provider. You are currently not authorized.

Site Information

Back to Trial Search